In a release issued earlier today by Biodel Inc. (Nasdaq: BIOD ), one reference to BIOD-238 should have been BIOD-250 in the fourth paragraph. The corrected paragraph follows: Local injection site discomfort was measured with a 100 mm visual analog scale (VAS) and patient questionnaires. 100 mm is defined as the worst possible discomfort